Acronym: MESOSCREEN
Study coordinator: Dr Vahan KEPENEKIAN
Malignant peritoneal mesothelioma (MPeM) is a rare primary neoplasm of the peritoneum, characterized by its aggressiveness and resistance to chemotherapy. It is usually diagnosed at a late stage, presenting with non-specific clinical signs that often indicate widespread disease.
Tumor genetic analyses, reported in several series, increasingly show that pleural mesothelioma (MPM) and peritoneal mesothelioma (MPeM) share a set of genetic alterations, but in different proportions, suggesting different responses to proposed treatments.
However, few data are currently available that correlate these genetic anomalies with the clinical outcomes of affected patients.
It is therefore essential to deepen our understanding of the genomics and transcriptomics of patients who develop this disease.
The objectives of the MESOSCREEN project are to characterize the genetic profile of a cohort of patients with MPeM using whole-exome and whole-genome sequencing data from both germline and tumor samples, to identify a prognostic gene signature, and to study, through transcriptomic data, the tumor immune microenvironment. The project also aims to identify synthetic lethality-based signatures predictive of treatment response.